丹参酮ⅡA磺酸钠联合瑞舒伐他汀治疗慢性心力衰竭的效果及其对血流动力学和心室重构的影响-现代医学

丹参酮ⅡA磺酸钠联合瑞舒伐他汀治疗慢性心力衰竭的效果及其对血流动力学和心室重构的影响

单位：1. 遂宁市中心医院心内科, 四川遂宁 629000;
2. 遂宁市中心医院检验科, 四川遂宁 629000

分类号：R541.6

出版年·卷·期（页码）：2019·47·第五期（561-565）

摘要：

目的：探讨丹参酮ⅡA磺酸钠联合瑞舒伐他汀治疗慢性心力衰竭（chronic heart failure，CHF）的效果及其对血流动力学和心室重构的影响。方法：选取本院收治的120例CHF患者，根据药物治疗方式的不同将患者分为研究组和对照组两组（各60例），研究组采用在常规药物治疗基础上加用丹参酮ⅡA磺酸钠联合瑞舒伐他汀治疗，对照组采用常规药物治疗，比较两组患者的临床疗效。结果：治疗前两组心功能及血流动力学相关指标差异均无统计学意义（P>0.05），治疗后心功能及血流动力学相关指标研究组均显著优于对照组（P<0.05）；治疗前两组影响心室重构的相关血清指标差异均无统计学意义（P>0.05），治疗后两组影响心室重构的相关血清指标均降低且研究组显著低于对照组（P<0.05）；治疗后研究组患者的主要不良心血管事件发生率为21.67%，显著低于对照组的38.33%（P<0.05）。结论：在常规药物治疗基础上加用丹参酮ⅡA磺酸钠和瑞舒伐他汀治疗CHF的效果显著，同时可有效改善患者血流动力学指标，延缓心室重构过程并且改善CHF预后，值得推广应用。

Objective:To investigate the efficacy of tanshinone ⅡA sulfonic acid natrium combined with rosuvastatin in the treatment of chronic heart failure and its effects on hemodynamics and ventricular remodeling. Methods:120 patients with CHF admitted to our department were enrolled. According to the different treatment methods, the patients were divided into study group and control group with 60 cases in each. The study group was treated with tanshinone ⅡA sulfonic acid natrium combined with rosuvastatin on top of the conventional drug therapy, and the control group was treated with the conventional drugs therapy. The clinical efficacy of the two groups was compared. Results:There were no significant differences in cardiac function related indexes between the two groups before treatment (P>0.05). After treatment, the cardiac function related indexes of the study group were significantly better than those of the control group (P<0.05). There were no differences in coronary hemodynamics between the two groups before treatment (P>0.05). After treatment, the coronary hemodynamics related indexes of the study group were significantly better than those of the control group (P<0.05). There were no differences in the related serum markers affecting ventricular remodeling between the two groups before treatment (P>0.05). After treatment, the related serum indexes affecting ventricular remodeling were decreased in the two groups, and these of the study group were significantly lower than those of the control group (P<0.05). The incidence of major adverse cardiovascular events in the study group after treatment (21.67%) was significantly lower than that in the control group (38.33%) (P<0.05). Conclusion:Tanshinone ⅡA sulfonic acid natrium combined with rosuvastatinon the top of the conventional drug therapy in the treatment of CHF patients is effective, and it can effectively improve hemodynamic parameters, delay the process of ventricular remodeling and improve the prognosis of patients. It is worthy of popularization and application.

参考文献：

[1] 贺文奇,楚英杰.老年急性失代偿心力衰竭患者临床特点及近期预后危险因素分析[J].中华老年医学杂志,2016,35(1):8-12.
[2] 吴铮,李文铮,程姝娟.瑞舒伐他汀强化治疗急性冠状动脉综合征疗效观察[J].新乡医学院学报,2015,32(11):1041-1044.
[3] 陈晨,金惠根.慢性心力衰竭治疗进展[J].国际心血管病杂志,2015,42(4):231-234.
[4] 孟立平,郭航远,蒋承建.慢性心力衰竭药物治疗研究进展[J].中国全科医学,2015,18(23):2870-2872.
[5] 常丽萍,魏聪,贾振华.复方中药防治慢性心力衰竭的发展浅析[J].中国老年学杂志,2016,36(16):4102-4105.
[6] 王贵鹏,吕忠英,向阳,等.环磷腺苷葡胺联合培哚普利在慢性心力衰竭中的应用研究[J].现代生物医学进展,2017,17(19):3707-3710,3768.
[7] 王喆.《中国心力衰竭诊断和治疗指南2014》解读[J].中国临床医生杂志,2016,44(5):14-16.
[8] MAMALYGA M L,MAMALYGA L M.Effect of progressive heart failure on cerebral hemodynamics and monoamine metabolism in CNS[J].Bull Exp Biol Med,2017,163(6):307-312.
[9] 祝婕,董薇,林建华.丹参酮ⅡA磺酸钠联合尼可地尔治疗冠心病稳定型心绞痛的临床疗效及其对血脂和血清同型半胱氨酸水平的影响[J].实用心脑肺血管病杂志,2017,25(2):107-110.
[10] 苏亚平,卜琳琳,李平平,等.丹参酮ⅡA注射液对急性心肌梗死大鼠钙调蛋白依赖性蛋白激酶Ⅱ表达及心肌收缩力的影响[J].中国中医急症,2016,25(2):204-207.
[11] 高文强,邱雪峰,李凯,等.丹参酮Ⅰ在肾脏缺血再灌注损伤中的保护作用研究[J].东南大学学报(医学版),2018,37(3):128-131.
[12] 中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):3-10.
[13] 焦云根,刘乃丰,孙晓宁,等.老年NSTEACS患者PCI术前负荷量瑞舒伐他汀对血清Lox-1、hs-CRP及近期预后的影响[J].东南大学学报(医学版),2015,5(1):71-76.
[14] 张慧,贺晓丹.研究高血压慢性心力衰竭患者左心室重构中应用比索洛尔的价值[J].临床医药文献电子杂志,2015,2(14):2888-2891.
[15] 郑俊华,唐浩然,景丽英,等.芪参益气滴丸联合阿托伐他汀对慢性心力衰竭患者心功能和BNP、TNF-α和IL-6的影响[J/OL].中华临床医师杂志(电子版),2014,8(16):41-44.
[16] TSUJITA K,SUGIYAMA S,SUMIDA H,et al.Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention:the multicenter randomized controlled PRECISE-IVUS trial[J].J Am Coll Cardiol,2015,66(5):495-507.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录